The main Irish manufacturing arm of Hong Kong-listed biopharma group WuXi Biologics last year recorded “expected” operating losses of €72.6 million.
The directors describe the firm’s main activity as providing manufacturing services to customers involved in the biologics industry globally. This strengthened the company’s balance sheet with shareholder funds rising from €799.3 million to €1.12 billion. On the company’s future developments, the directors state that during 2024, the company will complete the commissioning, qualification and validation of MFG6.2, “which will be dedicated to an existing client thereby doubling their manufacturing capacity”.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: